CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for DiaSorin SpA is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

DiaSorin SpA
via Crescentino snc
Phone: +39 0161487526p:+39 0161487526 SALUGGIA, 13040  Italy Ticker: DIADIA
Business Summary
DiaSorin SpA is an Italy-based company engaged in healthcare industry. The Company specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The Company develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company’s business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. It operates through ELISA immunodiagnostic business portfolio.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
3845 Electromedical and electrotherapeutic apparatus
2834 Pharmaceutical preparations
3826 Laboratory analytical instruments
8731 Commercial physical and biological research
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board MicheleDenegri 55 4/29/2022 3/26/2007
Chief Executive Officer, Executive Director, General Manager CarloRosa 58 3/26/2007 1/1/1998
Non-Executive Vice Chairman of the Board GiancarloBoschetti 84 4/29/2022 4/28/2016
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Diasorin Molecular LLC 11331 Valley View St. Cypress CA United States
Focus Diagnostics, Inc. 11331 Valley View Street Cypress CA United States
GenturaDx 24590 CLAWITER RD HAYWARD CA United States
4 additional Subsidiary records available in full report.

Business Names
Business Name
Amnis Corporation
Biotrin International Ltd.
DASOY
8 additional Business Names available in full report.

General Information
Number of Employees: 3,186 (As of 6/30/2024)
Outstanding Shares: 53,315,876 (As of 6/30/2024)
Stock Exchange: BIT
Fax Number: +39 0161487670


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, October 30, 2024